Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/14677
Full metadata record
DC FieldValueLanguage
dc.contributor.authorElina O. Erraen_US
dc.contributor.authorHelena Hervius Asklingen_US
dc.contributor.authorLars Romboen_US
dc.contributor.authorJukka Riuttaen_US
dc.contributor.authorSirkka Veneen_US
dc.contributor.authorSutee Yoksanen_US
dc.contributor.authorLars Lindquisten_US
dc.contributor.authorSari H. Pakkanenen_US
dc.contributor.authorEili Huhtamoen_US
dc.contributor.authorOlli Vapalahtien_US
dc.contributor.authorAnu Kanteleen_US
dc.contributor.otherUniversity of Helsinki Haartman Instituteen_US
dc.contributor.otherHelsinki University Hospitalen_US
dc.contributor.otherKarolinska Instituteten_US
dc.contributor.otherSormland County Councilen_US
dc.contributor.otherTravel Clinicen_US
dc.contributor.otherSwedish Institute for Communicable Disease Controlen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherHelsingin Yliopistoen_US
dc.date.accessioned2018-06-11T05:06:01Z-
dc.date.available2018-06-11T05:06:01Z-
dc.date.issued2012-09-01en_US
dc.identifier.citationClinical Infectious Diseases. Vol.55, No.6 (2012), 825-834en_US
dc.identifier.issn15376591en_US
dc.identifier.issn10584838en_US
dc.identifier.other2-s2.0-84865475058en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84865475058&origin=inwarden_US
dc.identifier.urihttp://repository.li.mahidol.ac.th/dspace/handle/123456789/14677-
dc.description.abstractBackground. A significant part of the world population lives in areas with endemic Japanese encephalitis (JE). For travelers from nonendemic countries, Vero cell-derived vaccine (JE-VC; Ixiaro) has replaced traditional mouse brain-derived vaccines (JE-MB) associated with safety concerns. The 2 vaccines are derived from different viral strains: JE-VC from the SA14-14-2 strain and JE-MB from the Nakayama strain. No data exist regarding whether JE-VC can be used to boost immunity after a primary series of JE-MB; therefore, a primary series of JE-VC has been recommended to all travelers regardless of previous vaccination history.Methods.One hundred twenty travelers were divided into 4 groups: Volunteers with no prior JE vaccination received primary immunization with (group 1) JE-MB or (group 2) JE-VC, and those primed with JE-MB received a single booster dose of (group 3) JE-MB or (group 4) JE-VC. Immune responses were tested before and 4-8 weeks after vaccination using plaque reduction neutralization test (PRNT) against both vaccine strains.Results.In vaccine-naive travelers, the vaccination response rate for test strains Nakayama and SA14-14-2 was 100 and 87 after primary vaccination with JE-MB and 87 and 94 after JE-VC, respectively. Antibody levels depended on the target virus, with higher titers against homologous than heterologous PRNT50 target strain (P < . 001). In travelers primed with JE-MB, vaccination response rates were 91 and 91, and 98 and 95 after a booster dose of JE-MB or JE-VC, respectively. Subgroup analysis revealed that a higher proportion of primed (98/95) than nonprimed (39/42) volunteers responded to a single dose of JE-VC (P < . 001).Conclusions.A single dose of JE-VC effectively boosted immunity in JE-MB-primed travelers. Current recommendations should be reevaluated. © 2012 The Author.en_US
dc.rightsMahidol Universityen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84865475058&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleA single dose of vero cell-derived Japanese encephalitis (JE) vaccine (ixiaro) effectively boosts immunity in travelers primed with mouse brain-derived JE vaccinesen_US
dc.typeArticleen_US
dc.rights.holderSCOPUSen_US
dc.identifier.doi10.1093/cid/cis542en_US
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.